
NASDAQHealthcareBiotechnology
Latest quote
$41.37
−$2.28 · -5.22%
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Previous close
$41.37
−$2.28 · -5.22%
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
71
Undervalued
Sentiment
47
Mixed
Risk
44
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Day range
Current $41.37
52-week range
Current $41.37
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 450.82M USD | 829.45M USD | 3.55M USD | 240.74M USD | 243.23M USD |
| Cost of goods sold | 1.8M USD | — | 18.6M USD | 12.49M USD | 10.42M USD |
| Gross profit | 449.02M USD | 829.45M USD | −15.04M USD | 228.24M USD | 232.81M USD |
| Research and development | 739.14M USD | 607.16M USD | 489.22M USD | 342.31M USD | 288.5M USD |
| Selling, general, and administrative | 202.05M USD | 121.92M USD | 96.82M USD | 90.93M USD | 124.43M USD |
| Operating expenses | 1.16B USD | 731.1M USD | 586.04M USD | 433.24M USD | 411.32M USD |
| Interest income | 57.86M USD | 37.29M USD | 22.72M USD | 15.3M USD | 5.03M USD |
| Interest expense | 93.71M USD | 89.36M USD | 32.35M USD | 18.33M USD | — |
| Depreciation and amortization | 26.62M USD | 23.93M USD | 18.6M USD | 12.49M USD | 10.42M USD |
| Operating income | −707.17M USD | 98.35M USD | −601.08M USD | −205M USD | −178.51M USD |
| Net income | −724.21M USD | −1.63M USD | −599.49M USD | −205.28M USD | −176.06M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$111.2
168.79% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 17, 2011 | 1:10 | — | — |
Stock split | Jan 15, 2004 | 1:65 | — | — |
Effective Nov 17, 2011
1:10
Effective Jan 15, 2004
1:65
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH210.55M0.18%115.06B USD0.05%$68.60-2.68%
Vanguard Morningstar Total Stock Market ETFVTI201.79M0.01%689.3B USD0.03%$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB180.2M0.10%78.7B USD0.03%$270.68-2.56%
Vanguard Morningstar Small-Cap Growth ETFVBK100.88M0.23%22.5B USD0.05%$298.35-3.85%
Vanguard Extended Market ETFVXF96M0.10%30.2B USD0.05%$211.44-3.21%
State Street SPDR S&P Biotech ETFXBI80.01M0.83%9.64B USD0.35%$140.18-2.73%
Invesco S&P MidCap Momentum ETFXMMO76.48M1.28%5.72B USD0.34%$123.11-4.15%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY46.16M0.19%24.52B USD0.23%$626.03-2.64%
iShares Core S&P Mid-Cap ETFIJH
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
State Street SPDR S&P Biotech ETFXBI
Invesco S&P MidCap Momentum ETFXMMO
State Street SPDR S&P MIDCAP 400 ETF TrustMDYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.